glp 1 agonist in heart failure Glucagon-like peptide receptor agonists: cardiovascular benefits and mechanisms of action GLP-1 receptor agonists and myocardial
Description
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 811 April 2024
Front Endocrinol (Lausanne) 2024;15 doi: 10.3389/fendo.2024.1431292
Lillys oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial | Eli Lilly and Company [Internet]
doi: 10.1172/JCI59903
